Everolimus and LongActing Octreotide Trial in Polycystic Livers

Inclusion Criteria: * 18 \< age ≤ 70 years * Polycystic liver disease (PCLD), defined as ≥ 20 liver cysts * Total liver volume must be at least 2500 mL * Symptomatic defined as ECOG-PS ≥ 1 (see fig 3.1)38, and having at least three out of ten PCLD symptoms: * Abdominal pain * Abdominal distension * Abdominal fullness * Dyspnea * Early satiety * Back pain * Nausea/vomiting * Anorexia * Weight loss * Jaundice * Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements Exclusion Criteria: * ADPKD patients * Use of oral anticonceptives or estrogen supplementation * Females who are pregnant or breast-feeding or patients of reproductive potential not employing an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to the administration of study medication. * Intervention (aspiration or surgical intervention) within three months before baseline * Treatment with somatostatin analogues within three months before baseline * Patients with a kidney transplant * History or other evidence of chronic pulmonary disease associated with functional limitation * History of severe cardiac disease (eg, NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases). In addition, patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled. * History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study * Symptomatic gallstones (octreotide decreases gall bladder volume) * Hypercholesterolemia (fasting cholesterol \> 8 mmol/l) or hypertriglyceridaemia (\> 5 mmol/l) not controlled by lipid lowering therapy * Granulocytopenia (white blood cell \< 3,000/mm3) or thrombocytopenia (platelets \< 100,000/mm3) * Infection with hepatitis B, hepatitis C, HIV, TBC (in medical history) * Mental illness that interferes with the patient ability to comply with the protocol * Drug or alcohol abuse within one year of baseline * Co-medication with strong inhibitor of CYP3A4 and or P-gp like voriconazole, ketoconazole, diltiazem, verapamil, erythromycin or with a strong CYP3A4 and or P-gp inductor like rifampicin * Known hypersensitivity to everolimus or one of its excipients * Enrolment in another clinical trial of an investigational agent while participating in this study * Moderate or severe reaction on contrast in medical history * Treatment with I131 during the course of the trial * Use of metformin * Morbus Kahler or Morbus Waldenstrom with excretion of light chains in urine in medical history * Kidney dysfunction (MDRD-GFR \< 60 ml/min/1.73m2 and ECC \< 60 ml/min, calculated by the Cockcroft-Gault formula); in case of decreased body muscle mass, exact ECC is measured using serum and urine creatinine